Form 4: MAIA Biotechnology CEO Vlad Vitoc Acquires 400,000 Stock Options
SEC Form 4 Filing
Vlad Vitoc, CEO of MAIA Biotechnology, Inc., reports the acquisition of 400,000 stock options on February 10, 2025, according to a Form 4 filing with the SEC.
Summary
- Vlad Vitoc, the CEO of MAIA Biotechnology, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on February 10, 2025.
- Vitoc acquired 400,000 stock options with an exercise price of $1.81.
- These options were granted pursuant to the company's 2021 Equity Incentive Plan.
- The options vest over a 4-year period, with 25% vesting on the first anniversary and the remainder vesting monthly over the following 36 months.
- The options expire on February 10, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance, but it's not a major event on its own.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term performance and commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders, particularly in companies focused on long-term research and development.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- The vesting schedule of 4 years with a 1-year cliff followed by monthly vesting is a typical structure to ensure long-term commitment.
- Comparable companies like Amgen, Gilead Sciences, and Biogen often use similar equity-based compensation plans to attract and retain top talent.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with theirs.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of stock options grant and transaction. |
| 02/10/2025 | Date the stock options were acquired. |
| 02/11/2025 | Date of signature on the Form 4 filing. |
| 02/10/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.